Genesis Therapeutics Closes Oversubscribed $200M Series B

Burlingame, CA, August 21, 2023 (Business Wire) -- Genesis Therapeutics, a pioneering company at the forefront of leveraging artificial intelligence (AI) technologies to revolutionize the drug development of cutting-edge treatments for severe diseases, has successfully concluded an oversubscribed Series B financing round, raising $200 million in funding. With this substantial injection of capital, Genesis is poised to advance its AI-enabled programs into clinical development, bolster its advanced AI platform, and aggressively broaden its portfolio of groundbreaking therapeutic discoveries.

Read full article here.